Back to top
more

National Vision (EYE)

(Real Time Quote from BATS)

$23.75 USD

23.75
2,558,506

-1.06 (-4.27%)

Updated Aug 6, 2025 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (166 out of 246)

Industry: Consumer Products - Staples

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 21.05% and 1.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold on to National Vision (EYE) for Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.

Zacks Equity Research

Abbott (ABT) Scales to a 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance by the Diabetes Care and Diagnostics businesses is driving the top line for Abbott (ABT).

Zacks Equity Research

Cardiovascular Systems (CSII) Business Down on COVID Resurgence

by Zacks Equity Research

According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.

Zacks Equity Research

Walgreens (WBA), VillageMD Plan to Expand Into Tampa, Florida

by Zacks Equity Research

Walgreens (WBA), VillageMD to open 20 new Village Medical at Walgreens primary care practices in the Tampa area to improve access to overall care for patients with chronic conditions.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.

Zacks Equity Research

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.

Zacks Equity Research

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

by Zacks Equity Research

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Zacks Equity Research

National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) revenues in the third quarter of 2021.

Zacks Equity Research

National Vision (EYE) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 52.00% and 0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

National Vision (EYE) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Earnings Preview: National Vision (EYE) Q3 Earnings Expected to Decline

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's Why You Should Hold on to Walgreens Boots (WBA) for Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.

Zacks Equity Research

Here's Why You Should Hold on to Hill-Rom (HRC) for Now

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.

Zacks Equity Research

3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.

Zacks Equity Research

Walgreens (WBA) to Make Additional Investment in VillageMD

by Zacks Equity Research

Walgreens (WBA) announced a $5.2-billion investment in VillageMD to bolster its strategic position in delivering value-based primary care.

Zacks Equity Research

National Vision (EYE) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) For Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma

Riya Anand headshot

4 Stocks to Keep a Watch on Amid Growing Optical Care Demand

by Riya Anand

Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Company News for Aug 13, 2021

by Zacks Equity Research

Companies In The News Are: CSIQ, DDS, EYE, AZEK